Predictive factors associated with prolonged survival in patients with advanced non-smallcell lung cancer (NSCLC) treated with gefitinib

被引：0
|
作者：
Satouchi, Miyako
Funada, Yasuhiro
Urata, Yoshiko
Shimada, Temiko
Yoshimura, Sho
Watanabe, Hirokazu
Kurata, Takayasu
Adachi, Shuji
Takada, Yoshiki
Negoro, Shunichi
机构：
[1] Hyogo Med Ctr Adults, Akashi, Hyogo, Japan
[2] Hyogo Med Ctr Adults, Akashi, Hyogo, Japan
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：231 / 231
页数：1
相关论文
共 50 条
  • [21] Inherited EGFR variants and survival in patients with non-small cell lung cancer (NSCLC) treated with gefitinib.
    Gregorc, V
    Hidalgo, M
    Spreafico, A
    Aondio, G
    Cusatis, G
    Marsh, S
    Steinberg, SM
    Ludovini, V
    Villa, E
    Sparreboom, A
    Baker, SD
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9079S - 9079S
  • [22] Survival predictors in advanced non-small cell lung cancer (NSCLC) patients with clinically proven sensitivity to gefitinib
    Lee, Y.
    Yun, T.
    Han, J.
    Kim, H.
    Lee, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Gefitinib (IRESSA) in advanced non small cell lung cancer (NSCLC): Response, survival and toxicity data
    Thomas, C
    Kassam, Z
    Shah, N
    BRITISH JOURNAL OF CANCER, 2004, 91 : S29 - S29
  • [24] The predictive values of carcinoembryonic antigen (CEA) in patients with metastatic non-small cell lung cancer (NSCLC) treated with gefitinib
    Bharwani, L. D.
    Lopes, G., Jr.
    Lim, E. H.
    Hsieh, W.
    Chang, A. Y.
    Shen, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] Potential clinical prognostic factors in non-small cell lung cancer (NSCLC) patients treated with Gefitinib (Iressa)
    Villaflor, VM
    Polowy, CR
    Coon, J
    Leslie, W
    Lukic, I
    Kanevsky, G
    Gale, M
    Stewart, I
    Bonomi, P
    LUNG CANCER, 2004, 46 : S62 - S62
  • [26] Potential clinical prognostic factors in non-small cell lung cancer (NSCLC) patients treated with gefitinib.
    Villaflor, VM
    Polowy, CR
    Coon, JS
    Leslie, WT
    Lukic, I
    Kanevsky, G
    Gale, M
    Stewart, I
    Bonomi, P
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 638S - 638S
  • [27] Efficacy of tumor treating fields (TTFields) and anti-PD-1 in non-smallcell lung cancer (NSCLC) preclinical models
    Giladi, M.
    Voloshin, T.
    Talyitzhaki, O.
    Weinberg, U.
    Kirson, E. D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC)
    Bearz, Alessandra
    Fratino, Lucia
    Spazzapan, Simon
    Berretta, Massimiliano
    Giacalone, Annalisa
    Simonelli, Cecilia
    Tirelli, Umberto
    LUNG CANCER, 2007, 55 (01) : 125 - 127
  • [29] Factors Associated With Survival in Patients With Oligometastatic Non-Small Cell Lung Cancer (NSCLC)
    Parikh, R. B.
    Cronin, A.
    Kozono, D. E.
    Oxnard, G. R.
    Mak, R. H.
    Jackman, D. M.
    Lo, P. C.
    Baldini, E. H.
    Johnson, B. E.
    Chen, A. B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S202 - S202
  • [30] Serum EGFR in patients with non-small cell lung cancer (NSCLC) treated with gefitinib
    Spreafico, A
    Gregorc, V
    Ludovini, V
    Pistola, L
    Amoroso, M
    Tofanetti, F
    Compagnoni, A
    Aondio, G
    Tonato, M
    Villa, E
    LUNG CANCER, 2005, 49 : S112 - S113
12345